GeoVax narrows quarterly loss to $4.16 million as funding runway extends through December

Key Facts

GeoVax reported a net loss of $4.16 million for the third quarter ended Sept. 30, 2026, compared with a loss of $6.32 million in the same period of 2025, according to its filing with the U.S. Securities and Exchange Commission. The year-over-year quarterly loss narrowed alongside lower research and development spending. Liquidity remains a central issue in the report: the company said available cash and access to its credit facility are sufficient to fund planned operations through December 2026. At the same time, it acknowledged substantial doubt about its ability to continue as a going concern. GOVX shares closed at $1.71 on Nov. 13, according to EL7 data.

Research and development expenses totaled $2,819,681 in the third quarter, down 44.1% from $5,043,504 a year earlier, according to the report. GeoVax attributed the decline mainly to the end of a contract with the U.S. Biomedical Advanced Research and Development Authority, known as BARDA, and lower costs for GEO-CM04S1 trials and Gedeptin manufacturing. This was partly offset by higher GEO-MVA manufacturing costs. These items show that lower spending resulted from changes in programs and contracts, rather than a general explanation based on cost-cutting efforts. The company also reported basic and diluted losses of $10.56 per share, compared with $150.68 in the third quarter of 2025, after retrospectively restating per-share data following the reverse stock split.

GeoVax announced on May 26, 2026, that it was halting active development activities for its GEO-CM04S1 COVID-19 vaccine candidate, then reiterated the decision in its third-quarter report. The company said the program's suspension was not related to vaccine safety concerns, but to a contracting COVID-19 vaccine market and the allocation of resources to programs it said had clearer regulatory pathways. The shift in priorities covered its development portfolio, not vaccines alone, with a stated focus on GEO-MVA and the Gedeptin program. The halt to GEO-CM04S1 development was therefore not a new announcement accompanying the quarterly results. The discontinued program also appears in the company's explanation for lower research and development costs.

Cash and cash equivalents totaled $2,150,946 on Sept. 30, 2026, compared with $3,085,741 on Dec. 31, 2025. GeoVax said its existing cash resources, together with access to its credit facility, would support planned operations through December 2026. However, the company acknowledged substantial doubt about its ability to continue as a going concern in the same report, making the securing of funding critical to carrying out its research plans. This disclosure places the timetable for upcoming programs in the context of the limited liquidity identified by the company. The report did not provide a later funding runway in the facts available here.

The company identified GEO-MVA, its candidate being developed against mpox and smallpox, as its near-term development priority. It plans to begin a pivotal Phase 3 clinical trial in late 2026, subject to funding availability, according to its report. The company said its European plan is based on scientific advice received from the European Medicines Agency in May 2025, and calls for moving directly to Phase 3, bypassing Phases 1 and 2. That path remains subject to final agreement on the protocol and regulatory requirements. The company's announced timing for the next phase is therefore tied to securing resources and completing regulatory arrangements.

For Gedeptin, GeoVax plans to begin a Phase 2 trial to evaluate the treatment in the second half of 2027, subject to funding availability. This is alongside its plan for GEO-MVA, while the company says the two programs face a funding horizon extending through December 2026 based on current resources and the credit facility. In September, the company reported that a hearing to appeal Nasdaq's decision concerning the minimum share price had been set for Oct. 13, 2026. It said the hearing request stayed suspension or delisting proceedings until the hearing and any extension granted by the panel. This remains part of the company's regulatory backdrop alongside the development path for its programs.